AURINIA PHARMACEUTICALS INC (AUPH) Stock News
NASDAQ:AUPH - Nasdaq - CA05156V1022 - Common Stock - Currency: USD
AUPH Latest News, Press Relases and Analysis
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors
Aurinia Pharmaceuticals (AUPH) shows strong growth, earnings momentum, and improving margins, making it a candidate for investors following Louis Navellier’s strategy.
Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
US Stocks Likely To Open On A Mixed Note: 'Nothing Good Happens Above A 5% Yield,' Says Expert
U.S. stock futures were fluctuating on Friday after a mixed close on Thursday. Futures of benchmark indices were mixed in premarket.
New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis
Company News for May 13, 2025
Companies in The News Are: NRG,FOX,AUPH,HBM
Aurinia Stock Rallies On Upbeat Q1 Earnings, CEO Expects Strong Performance in 2025: Retail Sentiment Brightens
The company also reiterated its full-year total revenue guidance of $250 million to $260 million and net product sales guidance of $240 million to $250 million.
Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of 100% and 2.63%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: DERM
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025
Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
Tariff turmoil: What P&G, Pepsi and other companies are saying about tariffs
Tariff worries continue hanging over companies as they report their latest financial results and try to provide guidance on their path ahead. The tariff and trade picture continues shifting and that makes it difficult for companies and investors to make a reliable assessment of any impact to costs and sales. Seemingly few industries or companies are being spared from the uncertainty.
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.
Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet
Over the past three months, Mainz has seen a staggering 2,500% increase in message volume on Stocktwits, while Aurinia’s engagement has grown just 23%.
Mentions: MYNZ
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress
Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
Aurinia to Participate in Jefferies London Healthcare Conference
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
